Argus
•
Oct 07, 2026
TGTX: Lowering target price to $57.00
Summary
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: BridgeBio Pharma, Inc.
Oct 30, 2026
•
BBIO
Analyst Report: Gilead Sciences, Inc.
Oct 30, 2026
•
GILD
Analyst Report: Merck & Co., Inc.
Oct 29, 2026
•
MRK
Analyst Report: BridgeBio Pharma, Inc.
Oct 28, 2026
•
BBIO
Technical Assessment: Bullish in the Intermediate-Term
Oct 28, 2026
•
MRK, ASML
